12 2 STA T .3985PUBLIC LA W 11 0– 35 4—O CT. 8 , 2008 ‘ ‘ (i ii )expandth en umb e rof re s ear c h proposa l s that in v olve collaboration bet w een 2 or more national research institutes or national centers , includin g pro - posals for C ommon F und research described in section 40 2(b)( 7 ) to improve the research portfolio
and ‘‘(iv) expand the number of collaborative, multi- disciplinar y , and multi-institutional research grants; ‘‘(C) develop a summary of advances in breast cancer research supported or conducted by Federal agencies rel- evant to the diagnosis, prevention, and treatment of cancer and other diseases and disorders; and ‘‘( D ) not later than 2 years after the date of the establishment of the Committee, ma k e recommendations to the S ecretary — ‘‘(i) regarding any appropriate changes to research activities, including recommendations to improve the research portfolio of the N ational I nstitutes of H ealth to ensure that scientifically-based strategic planning is implemented in support of research priorities that impact breast cancer research activities; ‘‘(ii) to ensure that the activities of the National Institutes of Health and other Federal agencies, including the Department of Defense, are free of unnecessary duplication of effort; ‘‘(iii) regarding public participation in decisions relating to breast cancer research to increase the involvement of patient advocacy and community organi z ations representing a broad geographical area; ‘‘(iv) on how best to disseminate information on breast cancer research progress; and ‘‘(v) on how to expand partnerships between public entities, including Federal agencies, and private enti- ties to expand collaborative, cross-cutting research . ‘‘( 3 ) RULEOFC O NSTR UCT I ON.—For the purposes of the Com- mittee, when focusing on research to evaluate environmental and genomic factors that may be related to the etiology of breast cancer, nothing in this section shall be construed to restrict the Secretary from including other forms of cancer, as appropriate, when doing so may advance research in breast cancer or advance research in other forms of cancer. ‘‘(4) M E MB ERS H I P .— ‘‘( A )IN G ENER A L.— T he Committee shall be composed of the following voting members
‘‘(i) Not more than 7 voting Federal representatives as follows: ‘‘(I) The Director of the Centers for Disease Control and P revention. ‘‘(II) The Director of the National Institutes of Health and the directors of such national research institutes and national centers (which may include the National Institute of E nviron- mental Health Sciences) as the Secretary deter- mines appropriate. ‘‘(III) O ne representative from the National Cancer Institute B oard of Scientific Advisors, appointed by the Director of the National Cancer Institute. Deadlin e .
�
